|
Hutchmed (China) Ltd on Friday said phase three results for its Fresco-2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer, conducted alongside Takeda Pharmaceutical Co Ltd, were published in peer-reviewed journal, The Lancet. The Hong Kong-based cancer and immunological diseases treatment developer said the publication shows how the treatment with fruquintinib reduced the risk of death by 34% in CRC patients. This comes after Hutchmed announced on Thursday that its marketing authorisation application for fruquintinib, alongside Tokyo-based Takeda, was validated and accepted by the European Medicines Agency. Fruiquintinib is an inhibitor of vascular endothelial growth factor receptors used to treat cancers. Shares in Hutchmed were up 2.9% at 213.00 pence each in London on Friday morning, while shares in Takeda had closed up 0.8% at JP¥4,572.00 each in Tokyo. Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
